Replies to post #210355 on Cytodyn Inc (CYDY)

[kgromax]

The paper that shows that Leronlimab has failed once again is from Cytodyn itself, no less:

https://events-program.easl.eu/ProgramSearch/?eventName=ilc2022&language=en-%20GB&searchString=leronlimab&pProgramGrade=Scientific&pShowPrivate=False&pHide%20Personal=False&pHideLogin=False&pTags=jh

Let me explain how to proceed:
- Look for the double blind part - here it’s part 1, the one with 700mg doses (part 2 with 350mg was not a double blind so not adequate to claim success)
- Look for it’s predefined primary endpoint - here it was PDFF
- Look if it met statistical significance for this endpoint -(and not something else) - here it was not met:

Mean percent change from baseline PDFF was significantly reduced in the 350 mg group … but not in the 700 mg group (+3.75% vs +9.85%, p = 0.135).

This is the basic procedure to check if a biotech trial can claim the « huge success «  that was promised. Of course clinical refinements and theories always abound to avoid following this. But this is a red flag.

So in this case… red flag like past trials. it’s obvious, but, like past trials, investors (and the stock) will only slowly abandon. It takes time to hear the true message. No wonder no biotech fund is interested by Cytodyn. No wonder no journo is recommending it. No wonder they use a toxic financier. No wonder they use stock promoters to pump the stock.